Goodbye CPAP? New sleep apnea pill cuts breathing events by 44%
A once-nightly pill cut breathing interruptions by about 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity. By strengthening the muscles that keep the airway open during sleep, AD109 could offer a new option for people unable to tolerate CPAP.
A new sleep apnea pill called AD109 significantly reduced breathing interruptions in obstructive sleep apnea patients during a large clinical trial. AD109 works by targeting the neuromuscular problems that cause airway collapse during sleep. In the SynAIRgy trial, 646 adults with mild to severe OSA who couldn't tolerate CPAP saw their apnea-hypoxia index decrease by 44 percent with AD109, compared to a 18 percent reduction in the placebo group.
The pill, which combines aroxybutynin and atomoxetine, showed no significant side effects and could offer an alternative treatment option for patients who struggle with CPAP. AD109 has received Fast Track designation from the FDA and is awaiting a potential PDUFA target action date in 2027.
Written by urgent.news from ScienceDaily's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Goodbye CPAP? New sleep apnea pill cuts breathing events by 44% sciencedaily.com
